Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141 ONCOLOGIST Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, L., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Jayaprakash, V., Wei, L., Ferris, R. L. 2022; 27 (2): E194-E198

View details for DOI 10.1093/oncolo/oyab036

View details for Web of Science ID 000764264500021